一个乙胆M1受体-阳性体调节器 (TAK-071) 在帕金森病与认知障碍:一个2期随机临床试验
Niraj M Shanbhag1, Jaya L Padmanabhan1, Zheng Zhang1
1Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
JAMA neurology
|January 6, 2025
概括
帕金森病 (PD) 的新药TAK-071在患有跌倒风险和认知障碍的患者中没有改善步态变化. 然而,与安慰剂相比,它在认知功能上显示出显著的改善.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 在神经退行性疾病的临床试验研究.
背景情况:
- 帕金森病 (PD) 经常伴有衰弱的跌倒风险和认知障碍.
- 迫切需要有效和安全的治疗方法来管理PD患者这些沉重的症状.
研究的目的:
- 为了评估TAK-071的安全性和有效性,一种肌肉蛋白M1受体阳性全调节剂.
- 评估TAK-071对患有PD,跌倒风险增加和认知缺陷的个体的步态变化和认知功能的影响.
主要方法:
- 第二阶段,随机,双盲,安慰剂控制,交叉试验,涉及54名患有PD的参与者.
- 参与者每天服用一次口服TAK-071或安慰剂6周,随后进行洗期和交叉治疗.
- 主要终点:步态变化 (步进时间变化[STV]);次要终点:认知综合评分的变化.
主要成果:
- 与安慰剂相比,TAK-071并没有显著改变步态变性 (STV),无论是有或没有认知负载.
- 与安慰剂相比,TAK-071显著改善了二级认知综合评分 (P=.01).
- 该药物一般耐受性良好,在TAK-071和安慰剂组之间,治疗出现的不良事件的发生率相似.
结论:
- 在患有PD,跌倒风险和认知障碍的参与者中,TAK-071耐受性良好.
- 虽然TAK-071并没有改善步态变性,但它对认知功能产生了积极影响.
- 需要在不同人群中进行更大,更长的研究来进一步证实这些发现.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...